Phase II study of maintenance carboplatin in patients with advanced epithelial ovarian cancer after complete response to platinum based combination

5122 Background: Five years survival of patients with advanced epithelial ovarian cancer (EOC) is 25–40% and once the disease recurs, treatment is mainly palliative. We evaluated whether continued ...